Vijay Singh
Mumbai (Maharashtra) [India], May 16: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), has announced the launch of ‘DAULCÉL’, its premium wellness and longevity-focused brand developed to cater to the growing demand for preventive healthcare, healthy aging, and lifestyle-oriented wellness solutions. The launch marks another strategic step in Fredun’s expansion into innovation-led and future-focused healthcare segments.
DAULCÉL is positioned as a premium wellness platform centered on quality, innovation, and evolving consumer wellness needs. The brand is aimed at addressing the increasing global focus on vitality, wellness optimization, recovery-focused healthcare, and long-term healthy living through scienceoriented wellness solutions.
The initiative complements Fredun Pharmaceuticals Limited’s existing pharmaceutical and healthcare capabilities while creating new opportunities within specialized wellness and longevity-driven categories. The launch also reflects the Company’s continued focus on building a diversified and future-ready healthcare portfolio.
Highlights
·First premium NAD+ based wellness offerings introduced in India’s emerging longevity and
·cellular wellness segment
·Launch of premium wellness and longevity-focused brand ‘DAULCÉL’
·Strategic expansion into preventive and lifestyle-oriented healthcare
·Focused on wellness, vitality, and healthy aging solutions
·Science-oriented and innovation-driven brand approach
·Expansion into emerging and high-growth wellness categories
·Strengthening Fredun’s specialty healthcare and wellness portfolio
·Leveraging the Company’s formulation and healthcare expertise
·Focused on differentiated, quality-driven wellness offerings
DAULCÉL’s initial portfolio is designed around premium wellness solutions aligned with the growing demand for advanced wellness, cellular vitality, and healthy lifestyle management. The brand aims to combine innovation, quality-focused development, and consumer-centric healthcare experiences to establish a differentiated presence within the evolving wellness market.
With increasing awareness around preventive wellness and longevity-focused healthcare globally, Fredun Pharmaceuticals Limited believes DAULCÉL is well-positioned to address emerging opportunities in the premium wellness segment while supporting the Company’s long-term growth and diversification strategy.
Commenting on the development, Mr. Fredun Medhora, Managing Director, said: “Daulcél reflects our focus on building future ready healthcare capabilities. Preventive health and longevity are becoming increasingly relevant, and we see strong potential in delivering science driven solutions that address these needs in a meaningful way.”
About Fredun Pharmaceuticals Limited
Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company’s objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
In the FY25, Fredun reported total revenues of ₹ 456 Cr, with an EBITDA of ₹ 55 Cr and a PAT of ₹ 21 Cr.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
